Devimistat (CPI-613)
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for Devimistat (CPI-613), covering 2013-08-14 to 2025-11-12. Get the full timeline:
Most recent: Clinical Trial Update: CPI-613 (Devimistat) in Combination With Chemoradiation in Patients With Pancreatic Adenocarcinoma [Phase 1]